CML Partnership 091012

Article

Recent Videos
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Pivotal Presentations That May Shape the Breast Cancer Standard of Care
The Role of Molecular Testing in Ovarian Cancer Care
The Role of Molecular Testing in Ovarian Cancer Care
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Managing Expectations: Adverse Events With Melanoma Immunotherapy
Managing Expectations: Adverse Events With Melanoma Immunotherapy
2 experts in this video
NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
2 experts in this video
Evaluating the Impact Of UGT1A1*28 Status On Tolerability Of NALIRIFOX In mPDAC
2 experts in this video
NAPOLI-3 in Real World Practice: Expert Insights on Data From ASCO GI 2025
2 experts in this video
Managing AEs Associated With the FOLFIRINOX and NALIRIFOX Regimens in Pancreatic Cancer
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
Nonimmune Adverse Effects: Managing Dysgeusia and Fatigue
Related Content
Treatment with KITE3-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

Novel CAR T-Cell Therapy Yields Responses in Relapsed/Refractory Lymphoma

Kristi Rosa
May 31st 2025
Article

Treatment with KITE3-363 yields no dose-limiting toxicities in a first-in-human phase 1 study.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

Safety Observed With T-DXd Rechallenge After ILD Instance in Breast/Solid Tumors

Chris Ryan
May 31st 2025
Article

T-DXd rechallenge occurred after grade 1 ILD, and was proven safe for patients with breast cancer/solid tumors.

ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

Gina Mauro
May 31st 2025
Article

Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.